Possible scenario
Regulated Pilot Scales
45% Chance
Nolla Health's acne-prescribing pilot operates without major safety incidents and is treated by regulators as a low-risk extension of telehealth. The FDA and state boards allow the model to expand gradually, especially for well-known dermatology drugs with established contraindication screening.
Secondary impacts
- Healthcare +0.6%
- Technology +0.5%
Tickers
- HIMS+2.4%
- TDOC+1.2%
- GDRX+1.2%
Portfolio impact
S&P 500+0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.